Carbocysteine: A potential therapy for alleviating hypoxic burden in patients with obstructive sleep apnea

Keywords

carbocysteine / hypoxic burden / obstructive sleep apnea / pharmacological therapy / secondary analysis

References

[1] Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA. Chest. 2015; 147(1): 266-274. https://doi.org/10.1378/chest.14-0500

[2] Trzepizur W, Blanchard M, Ganem T, et al. Sleep apnea-specific hypoxic burden, symptom subtypes, and risk of cardiovascular events and all-cause mortality. Am J Respir Crit Care Med. 2022; 205(1): 108-117. https://doi.org/10.1164/rccm.202105-1274OC

[3] Sawyer AM, Gooneratne NS, Marcus CL, Ofer D, Richards KC, Weaver TE. A systematic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions. Sleep Med Rev. 2011; 15(6): 343-356. https://doi.org/10.1016/j.smrv.2011.01.003

[4] Wu K, Su X, Li G, Zhang N. Antioxidant carbocysteine treatment in obstructive sleep apnea syndrome: a randomized clinical trial. PLoS One. 2016; 11(2):e0148519. https://doi.org/10.1371/journal.pone.0148519

[5] Azarbarzin A, Sands SA, Stone KL, et al. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Eur Heart J. 2019; 40(14): 1149-1157. https://doi.org/10.1093/eurheartj/ehy624

[6] Biswas SK, Rahman I. Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. Mol Aspects Med. 2009; 30(1–2): 60-76. https://doi.org/10.1016/j.mam.2008.07.001

[7] Wang W, Guan WJ, Huang RQ, et al. Carbocisteine attenuates TNF-α-induced inflammation in human alveolar epithelial cells in vitro through suppressing NF-κB and ERK1/2 MAPK signaling pathways. Acta Pharmacol Sin. 2016; 37(5): 629-636. https://doi.org/10.1038/aps.2015.150

RIGHTS & PERMISSIONS

2025 The Author(s). Sleep Research published by John Wiley & Sons Australia, Ltd on behalf of Chinese Sleep Research Society.